Biorestorative Therapies Inc (BRTX) 0.3400 $BRTX
BioRestorative Therapies Issues Letter to Stockholders
Business Wire - Mon Jul 14, 7:01AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, has issued a letter to stockholders, the text of which is below.
BioRestorative Therapies Appoints Joseph B. Swiader to its Board of Directors
Business Wire - Wed Jul 02, 7:00AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCBB: BRTX), a life sciences company focused on adult stem cell-based cellular therapies for various personal medical applications, today announced the appointment of Joseph B. Swiader, age 54, to its Board of Directors. Mr. Swiader will chair the Nominating Committee and serve on the Compensation Committee of the Board.
BioRestorative Therapies Appoints The Honorable Paul Jude Tonna to its Board of Directors
Business Wire - Mon Jun 30, 7:01AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCBB:BRTX), a life sciences company focused on adult stem cell-based cellular therapies for various personal medical applications, today announced the appointment of The Honorable Paul Jude Tonna to its Board of Directors. Mr. Tonna will serve on the Audit, Compensation and Nominating committees of the Board.
BioRestorative Therapies to Present at the Third Annual Marcum MicroCap Conference
Business Wire - Wed May 28, 1:32PM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCBB:BRTX), a life sciences company focused on adult stem cell-based cellular therapies for various personal medical applications, today announced that Mark Weinreb, the Company's President and Chief Executive Officer, and Francisco Silva, Vice President of Research and Development, will present at the Third Annual Marcum MicroCap Conference on Thursday, May 29th at 3:00 p.m. Eastern time in the Carnegie Room. The presentation will provide a corporate overview and a discussion of the Company's growth strategy. The conference will be held at the Grand Hyatt New York, 109 E. 42nd Street, in New York City.
Pfizer, BioRestorative Therapies Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 23, 4:30PM CDT
Pfizer (PFE) and BioRestorative Therapies (BRTX) inked a deal for studying human brown adipose tissue and cell lines.
BioRestorative Therapies Signs Research Agreement with Pfizer Inc.
Business Wire - Thu May 22, 7:00AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that it has entered into a two-year collaborative Research Agreement ("Agreement" with Pfizer Inc. ("Pfizer" to study human brown adipose tissue and cell lines.
BioRestorative Therapies Signs Research and Development Agreement with Rohto Pharmaceutical
Business Wire - Tue Mar 25, 8:42AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that it has entered into a Research and Development Agreement ("Agreement" with Rohto Pharmaceutical Company, Ltd. ("Rohto" . Under the Agreement, BRT has been engaged to provide stem cell research and development services.
BioRestorative Therapies Names Gregory Lutz, M.D. as Chief Medical Advisor for Spine Medicine
Business Wire - Mon Mar 03, 7:30AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that it has entered into a consulting agreement with Gregory Lutz, M.D. pursuant to which Dr. Lutz will serve as Chief Medical Advisor for Spine Medicine.
HMG Strategy Presents The 2014 CIO Summit of America - A Gathering of Global Executives in New York City
PR Newswire - Tue Jan 14, 12:54PM CST
HMG Strategy, the leading producer of CIO Executive Leadership Summits in North America, in partnership with the NY Metro Chapter of the Society for Information Management, will host the renowned CIO Summit of America on January 28, 2014 at The Harvard Club of New York City.
BioRestorative Therapies' Brown Fat Stem Cells Research Published in February Issue of Stem Cells Journal
Business Wire - Tue Jan 14, 10:51AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCBB: BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that a preclinical study that is part of its ThermoStem(R) program has been published in the February issue of the peer-reviewed journal, Stem Cells. A photograph of the Company's brown fat stem cell scaffold appears prominently on the cover. As previously announced, the newly identified human adult brown fat stem cells discussed in the study have the potential to lead to the development of a cell-based method for the treatment of type 2 diabetes and obesity.
OTC Daily Alert Stock Watch - BioRestorative Therapies, Inc. (OTCQB: BRTX)
WorldStockWire - Thu Aug 15, 8:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
BioRestorative Therapies Receives Approval to Conduct Retrospective Safety Study on its Bulging/Herniated Disc Procedure
PR Newswire - Tue Aug 06, 6:00AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTC BB: BRTX), a life sciences company focused on developing stem cell based cellular therapies for various personal medical applications, today announced that it has received approval from the Western Institutional Review Board ("the Board" to complete a retrospective safety study on selected subjects previously treated by the Company's brtxDISC(TM) bulging and herniated disc procedure. The study is titled "Re-consenting and Follow-Up of Adults from a Retrospective Study Using Autologous Transplantation of Marrow Derived Mesenchymal Stem Cells to Degenerated Intervertebral Disc."
BioRestorative Therapies Provides Company Updates with Shareholder Letter
PR Newswire - Thu Aug 01, 7:51AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTC BB: BRTX), a life sciences company focused on stem cell-based therapeutics, today announced the issuance of a shareholder letter by Chief Executive Officer, Mark Weinreb, providing an update to shareholders on the Company's progress.
BioRestorative Therapies CEO Mark Weinreb Interviewed by The Life Sciences Report
Marketwire - Thu Jul 25, 1:01PM CDT
"Millions of people suffer back pain caused by herniated and bulging disc disease. When conventional medical therapies fail, they often resort to surgery for relief, a costly and time-consuming solution for both patients and the medical system. In this interview with The Life Sciences Report, Mark Weinreb, president, CEO and chairman of BioRestorative Therapies Inc. (OTCQB: BRTX), describes how his company's cell therapy process could keep disc disease treatment out of the operating theater.
BioRestorative Therapies Expands its ThermoStem® Program to 150 Stem Cell Lines
PR Newswire - Mon Jun 24, 7:19AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTC BB: BRTX), a life sciences company focused on stem cell-based therapeutics, announced that it has expanded its ThermoStem® Program by collecting 150 samples of human brown adipose tissue (BAT). For the past year, through strategic collaboration and internal BRT efforts, the Company has grown a large library of human brown fat stem cells. The ThermoStem® Program, which is in the pre-clinical stage, focuses on the development of therapies using adult derived stem cells from brown adipose tissue to treat metabolic and obesity related disorders (particularly focusing on Type 2 Diabetes). The compilation of a large number and variety of brown fat derived stem cells allows BRT to study and identify potential cell lines to be used in developing therapies.
BioRestorative Therapies CEO Mark Weinreb Interviewed on "Next Big Thing" with Financial Personality and Founder Tobin Smith
PR Newswire - Mon Jun 17, 7:00AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTC BB: BRTX) - Financial personality and Founder of NBT Equities Research, Tobin Smith, recently interviewed BioRestorative Therapies, Inc. (the "Company" CEO, Mark Weinreb, on the firm's hybrid business model and what the firm is currently doing that will help change the biotechnology landscape. BioRestorative is a life sciences company focused on developing stem cell based cellular therapies for various personal medical applications.
BioRestorative Therapies Announces the Development of an Extract that has Promise for Use in Beauty Care Products
PR Newswire - Wed May 29, 6:00AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTC BB: BRTX), a life sciences company focused on developing stem cell based cellular therapies for various personal medical applications, today announced that it has developed a human cellular-derived extract that, per initial in vitro studies, when applied to skin cells, appears to cause a significant increase in collagen and fibronectin production (proteins that are essential for combating the aging of skin). BRT plans to conduct additional in vitro studies to better understand the extract's mechanism of action and human cellular activity.
BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference
PR Newswire - Tue May 21, 6:00AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announced that Mark Weinreb, its President and CEO, will be presenting at the Marcum MicroCap Conference.
BioRestorative Therapies Signs Agreement with Dexterity, Inc. to Advance Production of the Company's Novel brtxDISC(TM) Stem Cell Therapy Device
PR Newswire - Mon May 20, 7:00AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announces the signing of a consulting agreement with Dexterity, Inc. ("Dexterity" . Dexterity is a product design and bioengineering firm that will provide services to further the development and production of BRT's proprietary therapeutic delivery device for its intervertebral disc stem cell therapy program, "brtxDISC(TM)," (Disc Implanted Stem Cells).
BioRestorative Therapies Invited to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria
PR Newswire - Tue Apr 16, 9:25AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company" (OTCBB: BRTX), a life sciences company focused on adult stem cell based cellular therapies for various personal medical applications, announced today that it has been invited to present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria. The conference will take place April 18th-20th, 2013 at the Austria Center Vienna and will highlight early interventions for diabetes, dysglycemia, and surgery in the treatment of obesity and diabetes, where world leaders and specialists will discuss pioneering research in these areas.
BioRestorative Therapies Issues Letter to Stockholders
Business Wire - Mon Jul 14, 7:01AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, has issued a letter to stockholders, the text of which is below. BioRestorative Therapies Appoints Joseph B. Swiader to its Board of Directors
Business Wire - Wed Jul 02, 7:00AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB: BRTX), a life sciences company focused on adult stem cell-based cellular therapies for various personal medical applications, today announced the appointment of Joseph B. Swiader, age 54, to its Board of Directors. Mr. Swiader will chair the Nominating Committee and serve on the Compensation Committee of the Board. BioRestorative Therapies Appoints The Honorable Paul Jude Tonna to its Board of Directors
Business Wire - Mon Jun 30, 7:01AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB:BRTX), a life sciences company focused on adult stem cell-based cellular therapies for various personal medical applications, today announced the appointment of The Honorable Paul Jude Tonna to its Board of Directors. Mr. Tonna will serve on the Audit, Compensation and Nominating committees of the Board. BioRestorative Therapies to Present at the Third Annual Marcum MicroCap Conference
Business Wire - Wed May 28, 1:32PM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB:BRTX), a life sciences company focused on adult stem cell-based cellular therapies for various personal medical applications, today announced that Mark Weinreb, the Company's President and Chief Executive Officer, and Francisco Silva, Vice President of Research and Development, will present at the Third Annual Marcum MicroCap Conference on Thursday, May 29th at 3:00 p.m. Eastern time in the Carnegie Room. The presentation will provide a corporate overview and a discussion of the Company's growth strategy. The conference will be held at the Grand Hyatt New York, 109 E. 42nd Street, in New York City. Pfizer, BioRestorative Therapies Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 23, 4:30PM CDT
Pfizer (PFE) and BioRestorative Therapies (BRTX) inked a deal for studying human brown adipose tissue and cell lines.
BioRestorative Therapies Signs Research Agreement with Pfizer Inc.
Business Wire - Thu May 22, 7:00AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that it has entered into a two-year collaborative Research Agreement ("Agreement" with Pfizer Inc. ("Pfizer" to study human brown adipose tissue and cell lines. BioRestorative Therapies Signs Research and Development Agreement with Rohto Pharmaceutical
Business Wire - Tue Mar 25, 8:42AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that it has entered into a Research and Development Agreement ("Agreement" with Rohto Pharmaceutical Company, Ltd. ("Rohto" . Under the Agreement, BRT has been engaged to provide stem cell research and development services. BioRestorative Therapies Names Gregory Lutz, M.D. as Chief Medical Advisor for Spine Medicine
Business Wire - Mon Mar 03, 7:30AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that it has entered into a consulting agreement with Gregory Lutz, M.D. pursuant to which Dr. Lutz will serve as Chief Medical Advisor for Spine Medicine. HMG Strategy Presents The 2014 CIO Summit of America - A Gathering of Global Executives in New York City
PR Newswire - Tue Jan 14, 12:54PM CST
HMG Strategy, the leading producer of CIO Executive Leadership Summits in North America, in partnership with the NY Metro Chapter of the Society for Information Management, will host the renowned CIO Summit of America on January 28, 2014 at The Harvard Club of New York City.
BioRestorative Therapies' Brown Fat Stem Cells Research Published in February Issue of Stem Cells Journal
Business Wire - Tue Jan 14, 10:51AM CST
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB: BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that a preclinical study that is part of its ThermoStem(R) program has been published in the February issue of the peer-reviewed journal, Stem Cells. A photograph of the Company's brown fat stem cell scaffold appears prominently on the cover. As previously announced, the newly identified human adult brown fat stem cells discussed in the study have the potential to lead to the development of a cell-based method for the treatment of type 2 diabetes and obesity. OTC Daily Alert Stock Watch - BioRestorative Therapies, Inc. (OTCQB: BRTX)
WorldStockWire - Thu Aug 15, 8:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
BioRestorative Therapies Receives Approval to Conduct Retrospective Safety Study on its Bulging/Herniated Disc Procedure
PR Newswire - Tue Aug 06, 6:00AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTC BB: BRTX), a life sciences company focused on developing stem cell based cellular therapies for various personal medical applications, today announced that it has received approval from the Western Institutional Review Board ("the Board" to complete a retrospective safety study on selected subjects previously treated by the Company's brtxDISC(TM) bulging and herniated disc procedure. The study is titled "Re-consenting and Follow-Up of Adults from a Retrospective Study Using Autologous Transplantation of Marrow Derived Mesenchymal Stem Cells to Degenerated Intervertebral Disc." BioRestorative Therapies Provides Company Updates with Shareholder Letter
PR Newswire - Thu Aug 01, 7:51AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTC BB: BRTX), a life sciences company focused on stem cell-based therapeutics, today announced the issuance of a shareholder letter by Chief Executive Officer, Mark Weinreb, providing an update to shareholders on the Company's progress. BioRestorative Therapies CEO Mark Weinreb Interviewed by The Life Sciences Report
Marketwire - Thu Jul 25, 1:01PM CDT
"Millions of people suffer back pain caused by herniated and bulging disc disease. When conventional medical therapies fail, they often resort to surgery for relief, a costly and time-consuming solution for both patients and the medical system. In this interview with The Life Sciences Report, Mark Weinreb, president, CEO and chairman of BioRestorative Therapies Inc. (OTCQB: BRTX), describes how his company's cell therapy process could keep disc disease treatment out of the operating theater.
BioRestorative Therapies Expands its ThermoStem® Program to 150 Stem Cell Lines
PR Newswire - Mon Jun 24, 7:19AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTC BB: BRTX), a life sciences company focused on stem cell-based therapeutics, announced that it has expanded its ThermoStem® Program by collecting 150 samples of human brown adipose tissue (BAT). For the past year, through strategic collaboration and internal BRT efforts, the Company has grown a large library of human brown fat stem cells. The ThermoStem® Program, which is in the pre-clinical stage, focuses on the development of therapies using adult derived stem cells from brown adipose tissue to treat metabolic and obesity related disorders (particularly focusing on Type 2 Diabetes). The compilation of a large number and variety of brown fat derived stem cells allows BRT to study and identify potential cell lines to be used in developing therapies. BioRestorative Therapies CEO Mark Weinreb Interviewed on "Next Big Thing" with Financial Personality and Founder Tobin Smith
PR Newswire - Mon Jun 17, 7:00AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTC BB: BRTX) - Financial personality and Founder of NBT Equities Research, Tobin Smith, recently interviewed BioRestorative Therapies, Inc. (the "Company" CEO, Mark Weinreb, on the firm's hybrid business model and what the firm is currently doing that will help change the biotechnology landscape. BioRestorative is a life sciences company focused on developing stem cell based cellular therapies for various personal medical applications. BioRestorative Therapies Announces the Development of an Extract that has Promise for Use in Beauty Care Products
PR Newswire - Wed May 29, 6:00AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTC BB: BRTX), a life sciences company focused on developing stem cell based cellular therapies for various personal medical applications, today announced that it has developed a human cellular-derived extract that, per initial in vitro studies, when applied to skin cells, appears to cause a significant increase in collagen and fibronectin production (proteins that are essential for combating the aging of skin). BRT plans to conduct additional in vitro studies to better understand the extract's mechanism of action and human cellular activity. BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference
PR Newswire - Tue May 21, 6:00AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announced that Mark Weinreb, its President and CEO, will be presenting at the Marcum MicroCap Conference. BioRestorative Therapies Signs Agreement with Dexterity, Inc. to Advance Production of the Company's Novel brtxDISC(TM) Stem Cell Therapy Device
PR Newswire - Mon May 20, 7:00AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announces the signing of a consulting agreement with Dexterity, Inc. ("Dexterity" . Dexterity is a product design and bioengineering firm that will provide services to further the development and production of BRT's proprietary therapeutic delivery device for its intervertebral disc stem cell therapy program, "brtxDISC(TM)," (Disc Implanted Stem Cells). BioRestorative Therapies Invited to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria
PR Newswire - Tue Apr 16, 9:25AM CDT
BioRestorative Therapies, Inc. ("BRT" or the "Company"
(OTCBB: BRTX), a life sciences company focused on adult stem cell based cellular therapies for various personal medical applications, announced today that it has been invited to present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria. The conference will take place April 18th-20th, 2013 at the Austria Center Vienna and will highlight early interventions for diabetes, dysglycemia, and surgery in the treatment of obesity and diabetes, where world leaders and specialists will discuss pioneering research in these areas. 
